Education
About Us
Working with TipRanks
Follow Us
Centogene (CNTGF)
OTHER OTC:CNTGF
CNTGF Stock Chart & Stats
$0.12
<$0.01(2.52%)
At close: 4:00 PM EST
$0.12
<$0.01(2.52%)
Day’s Range― - ―
52-Week Range$0.01 - $0.71
Previous CloseN/A
Volume282.00
Average Volume (3M)1.26K
Market Cap
$3.19M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-3.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,817,080
10 Day Avg. Volume717
30 Day Avg. Volume1,260
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Model StrengthCentogene's business model leverages its expertise in rare disease diagnostics and genetic testing, providing stable revenue streams through long-term contracts and collaborative research agreements with pharmaceutical companies.
Strategic PartnershipsStrategic partnerships with pharmaceutical companies enhance Centogene's market position, offering growth opportunities through drug development support and biomarker discovery, which are crucial for long-term success in the biotech sector.
Data Monetization PotentialThe company's genetic database offers significant monetization potential through licensing and data-driven projects, providing a competitive edge and additional revenue streams in the evolving field of precision medicine.
Bears Say
High LeverageHigh leverage poses a risk to Centogene's financial health, limiting its ability to invest in growth opportunities and increasing vulnerability to economic downturns, which could impact long-term sustainability.
Negative Cash FlowPersistent negative cash flow reflects operational inefficiencies and reliance on external financing, which could hinder Centogene's ability to fund future growth and maintain financial stability over time.
Stagnant Revenue GrowthStagnant revenue growth highlights challenges in expanding market share and increasing sales, which could impede Centogene's ability to achieve profitability and sustain its competitive position in the long term.
Centogene News
CNTGF FAQ
What was Centogene’s price range in the past 12 months?
Centogene lowest stock price was $0.01 and its highest was $0.70 in the past 12 months.
What is Centogene’s market cap?
Centogene’s market cap is $3.19M.
When is Centogene’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Centogene’s earnings last quarter?
Currently, no data Available
Is Centogene overvalued?
According to Wall Street analysts Centogene’s price is currently Overvalued.
Does Centogene pay dividends?
Centogene does not currently pay dividends.
What is Centogene’s EPS estimate?
Centogene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Centogene have?
Centogene has 29,817,080 shares outstanding.
What happened to Centogene’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Centogene?
Currently, no hedge funds are holding shares in CNTGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Centogene
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Technical Analysis
Aethlon Medical
―
Enveric Biosciences
―
Revelation Biosciences
―
Universe Pharmaceuticals
―
Azitra Inc
―
Ownership Overview
―
Insiders
0.60% Other Institutional Investors
99.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---